Cadent Therapeutics Stock

cadenttx.comBioTechFounded: 2010Funding to Date: $67.4MM

Developer of a drug development platform intended to focus on medicines for psychiatric diseases. The company's platform develops small molecule therapeutics targeting the NMDA receptor to treat neuropsychiatric disorders, schizophrenia and other cognitive and neuropsychiatric disorders, enabling patients to cure various neurological diseases.

Register for Details

For more details on financing and valuation for Cadent Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Michael Curtis Ph.D
President & Chief Executive Officer
John McBride
Chief Financial Officer
Timothy Piser Ph.D
Chief Scientific Officer
Christopher Kenney
Chief Medical Officer
David Anderson Ph.D
Head of Discovery Operations
Robert Volkmann Ph.D
Vice President of Chemistry & Advisor

Board Members

Benjamin Bronstein MD
Clal Biotechnology Industries
Daniel Behr
David Grayzel MD
Atlas Venture
Franz Hefti
Cadent Therapeutics
James Bristol Ph.D
Mark McDade
Qiming Venture Partners
Paul Wotton Ph.D
Peter Barrett Ph.D
Atlas Venture
Richard Horan
Slater Technology Fund
Timothy Anderson
Cowen Group
William Koster Ph.D
Clal Biotechnology Industries

Other companies like Cadent Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM